Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.…
How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company
Kiora Pharmaceuticals (NASDAQ: KPRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 0.7202 USD on 20 November 2026, down 69.1% over 52 weeks. Its 52-week range is 0.7202 USD to 2.910 USD, and it trades at the bottom of that range.
Its market capitalisation is 3.19M USD.
Kiora Pharmaceuticals reports return on equity of -67.2%.
It holds more cash than debt, a net cash position of 16.00M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.